FrancophonIA/ELRC3.0 huggingface dataset:
English: Of the patients with grade 3 or 4 liver-associated laboratory toxicity, the proportions coinfected with hepatitis B or hepatitis C virus were 6.7 % and 20.0 % in the nevirapine twice daily group, 5.6 % and 11.1 % in the efavirenz group.
Slovenian: Med bolniki, ki so imeli z jetri povezan laboratorijski toksični učinek 3. ali 4. stopnje, je bil delež bolnikov s sočasno okužbo z virusom hepatitisa B ali hepatitisa C 6,7 % oziroma 20,0 % v skupini, ki je jemala dvakrat na dan nevirapin, in 5,6 % oziroma 11,1 % v skupini, ki je jemala efavirenz.
English: The side effects described below have been experienced by patients given Viramune prolonged-release tablets once daily in the maintenance phase:
Slovenian: Neželeni učinki, opisani v nadaljevanju so se pojavili pri bolnikih, ki so jemali zdravilo Viramune tablete s podaljšanim sproščanjem enkrat na dan v fazi vzdrževanja:
English: Time to emergence of nevirapine resistance in cell culture was not altered when selection included nevirapine in combination with several other NNRTIs.
Slovenian: Čas do pojava odpornosti proti nevirapinu v celični kulturi se ni spremenil, če so nevirapin uporabili v kombinaciji z več drugimi nenukleozidnimi zaviralci reverzne transkriptaze.
English: The dose of Viramune may need adjusting.
Slovenian: Odmerek zdravila Viramune je včasih treba prilagoditi.
English: administered without dose adjustments.
Slovenian: brez prilagajanja odmerkov.
English: Nevirapine had a median EC50 value (50% inhibitory concentration) of 63 nM against a panel of group M HIV-1 isolates from clades A, B, C, D, F, G, and H, and circulating recombinant forms (CRF), CRF01_AE, CRF02_AG and CRF12_BF replicating in human embryonic kidney 293 cells.
Slovenian: Srednja vrednost EC50 nevirapina (ob 50 % zaviralni koncentraciji) je bila 63 nM proti naboru izolatov HIV-1 iz skupine M genotipskih skupin A, B, C, D, F, G in H ter rekombinantnim oblikam v obtoku (CRF), CRF01_AE, CRF02_AG in CRF12_BF, ki se razmnožujejo v človeških embrionalnih ledvičnih celicah 293.
English: Additional side effects in children and adolescents A reduction in white blood cells (granulocytopenia) can occur, which is more common in children.
Slovenian: Dodatni neželeni učinki pri otrocih in mladostnikih Zmanjša se lahko število belih krvničk (granulocitopenija), ki je pri otrocih pogostnejša.
English: Cimetidine: no significant effect on cimetidine PK parameters is seen.
Slovenian: Cimetidin: ni pomembnejšega vpliva na cimetidinove farmakokinetične parametre.
English: Viramune 50 mg/5 ml Oral suspension and Viramune 400 mg and 100 mg prolonged-release tablets
Slovenian: Viramune 50 mg/5 ml peroralna suspenzija in Viramune 400 mg in 100 mg, tablete s podaljšanim sproščanjem
English: Virologic responder (HIV-1 RNA <50 copies/ml)
Slovenian: Bolnik z virološkim odzivom (HIV-1 RNK < 50 kopij/ml)
English: Total * Includes patients who received at least one dose of blinded medicinal product after randomisation.
Slovenian: skupna * Zajema bolnike, ki so prejeli vsaj en odmerek prikritega zdravila po naključni razvrstitvi.
English: ANALGESICS/OPIOIDS Methadone Individual Patient Dosing
Slovenian: ANALGETIKI/ OPIOIDI Metadon, individualni odmerki
English: The bottle can be kept sealed with the lid of the plastic adapter.
Slovenian: Plastenka je lahko med shranjevanjem zaprta s pomičnim adapterjevim pokrovčkom.
English: The proportion of patients with at least one grade 3 or 4 liver-associated laboratory toxicity was 8.3 % for nevirapine twice daily and 4.5 % for efavirenz.
Slovenian: Delež bolnikov z najmanj enim laboratorijskim toksičnim učinkom 3. ali 4. stopnje, povezanim z jetri, je bil 8,3 % pri jemanju dveh odmerkov nevirapina na dan, in 4,5 % pri jemanju efavirenza.
English: If you are taking nevirapine and zidovudine concomitantly please inform your doctor since he might need to check your white blood cells.
Slovenian: O sočasnem jemanju nevirapina in zidovudina obvestite svojega zdravnika, ker boste morda potrebovali preiskavo belih krvničk.
English: Viramune is also available as 200 mg tablets for adults (16 years of age and older).
Slovenian: Zdravilo Viramune je na voljo tudi v obliki tablet po 200 mg za odrasle bolnike (16 let in starejše).
English: All patients less than 16 years of age receiving Viramune oral suspension should have their weight or BSA checked frequently to assess if dose adjustments are necessary.
Slovenian: Vsem bolnikom, mlajšim od 16 let, ki prejemajo peroralno suspenzijo Viramune, je treba pogosto preverjati telesno maso ali telesno površino, da bi ugotovili, ali je treba odmerek ponovno prilagoditi.
English: Lipids, Change from baseline Changes from baseline in fasting lipids are shown in Table 4.
Slovenian: Lipidi, sprememba v primerjavi z izhodiščno vrednostjo Spremembe ravni lipidov na tešče v primerjavi z izhodiščno ravnijo so prikazane v preglednici 4.
English: Make sure that the syringe is tightly inserted.
Slovenian: Preverite, ali je brizga trdno pritrjena.
English: Genotypic analysis was performed on isolates from 86 antiretroviral naïve patients who discontinued the VERxVE study (1100.1486) after experiencing virologic failure (rebound, partial response) or due to an adverse event or who had transient increase in viral load during the course of the study.
Slovenian: Genotipsko so analizirali izolate 86 bolnikov, ki v preteklosti še niso jemali protiretrovirusnih zdravil, in ki so prekinili študijo VERxVE (1100.1486) po virološkem neuspehu (ponovnem pojavu, delnem odgovoru) ali zaradi neželenega dogodka ali se jim je virusno breme med študijo prehodno povečalo.
English: The observed pharmacokinetic difference between the 50 mg and 100 mg Viramune prolonged-release tablets is not clinically relevant, and the 50 mg prolonged-release tablet can be used as an alternative to the slightly larger 100 mg tablet.
Slovenian: Farmakokinetična razlika med zdravilom Viramune 50 mg in 100 mg tablete s podaljšanim sproščanjem ni klinično pomembna, 50 mg tableta s podaljšanim sproščanjem je lahko alternativa nekoliko večji 100 mg tableti.
English: In study 1100.1090, from which the majority of related adverse events (n=28) were received, patients on placebo had a higher incidence of events of granulocytopenia (3.3 %) than patients on nevirapine
Slovenian: V študiji 1100.1090, iz katere izvira večina podatkov o povezanih neželenih dogodkih (n=28), je bila pojavnost granulocitopenije večja pri bolnikih, ki so prejemali placebo (3,3 %), kot pri bolnikih, ki so prejemali nevirapin (2,5 %).
English: Nevirapine: Co-administration of ritonavir does not lead to any clinically relevant change in nevirapine plasma levels.
Slovenian: Nevirapin: Sočasno dajanje ritonavirja ne povzroči nikakršne klinično pomembne spremembe ravni nevirapina v plazmi.
English: Methadone-maintained patients beginning Viramune therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.
Slovenian: Bolnike na metadonu, pri katerih uvedemo zdravljenje z zdravilom Viramune, je treba spremljati, da bi odkrili znake odtegnitve, in odmerek metadona ustrezno prilagoditi.
English: Nevirapine is about 60% bound to plasma proteins in the plasma concentration range of 1-10 µg/ml.
Slovenian: Približno 60 % nevirapina se pri razponu plazemskih koncentracij 1 do 10 µg/ml veže na beljakovine v plazmi.
English: White high density polyethylene (HDPE) bottle with two piece child-resistant closure (outer shell white high density polyethylene, inner shell natural polypropylene) with a low density polyethylene (LDPE) foam liner.
Slovenian: Bela plastenka iz polietilena visoke gostote (HDPE) z dvodelnim, za otroke varnim zapiralom (zunanji del je iz belega polietilena visoke gostote, notranji iz naravnega polipropilena) z oblogo iz penastega polietilena nizke gostote (LDPE).
English: Viramune tablets are supplied in blisters, with 14, 60 or 120 tablets per carton.
Slovenian: Tablete Viramune so na voljo v pretisnih omotih po 14, 60 ali 120 tablet v škatli.
English: For children, increase of the dose of lopinavir/ritonavir to 300/75 mg/m twice daily with food should be considered when used in combination with Viramune, particularly for patients in whom reduced susceptibility to lopinavir/ritonavir is suspected.
Slovenian: Pri otrocih je potrebno presoditi o povečanju odmerjanja kombinacije lopinavirja in ritonavirja na 2-krat 300 mg/m2 in 75 mg/m2 ob jedi, kadar jo uporabljamo v kombinaciji z zdravilom Viramune, zlasti pri bolnikih, pri katerih sumimo na zmanjšano občutljivost za kombinacijo lopinavirja in ritonavirja.
English: No life-threatening (Grade 4) rash events considered related to Viramune were reported during the randomised phase of this study.Six cases of Stevens-Johnson Syndrome were reported in the study; all but one occurred within the first 30 days of nevirapine treatment.
Slovenian: V fazi naključne razvrstitve v tej raziskavi niso poročali o življenjsko nevarnih primerih izpuščaja (4. stopnji), ki bi bili povezani z zdravilom Viramune.V študiji so poročali o šestih primerih Stevens-Johnsonovega sindroma;, vsi razen enega so se pojavili v prvih 30 dneh zdravljenja z nevirapinom.
English: Women appear to be at higher risk than men of developing rash, whether receiving nevirapine or non-nevirapine containing therapy.
Slovenian: Kaže, da je tveganje pojava izpuščaja pri ženskah večje kot pri moških ne glede na to, ali prejemajo zdravljenje, ki vključuje nevirapin, ali takšno, ki ga ne vsebuje.
English: Combination of other antiretrovirals with single-dose nevirapine attenuates the emergence of nevirapine resistance.
Slovenian: Kombiniranje drugih protiretrovirusnih zdravil z enkratnim odmerkom nevirapina zmanjša pojav odpornosti proti njemu.
English: The predetermined primary efficacy comparison was between the Viramune twice daily and the efavirenz treatment groups.
Slovenian: Vnaprej opredeljena primarna primerjava za oceno učinkovitosti je potekala med skupinama, kjer je prva prejemala zdravilo Viramune dvakrat na dan, druga pa efavirenz.
English: EE Cmax  0.94 (0.79 - 1.12)
Slovenian: Cmax EE  0,94 (0,79-1,12)
English: Patients who are already on immediate-release tablets or oral suspension can switch to prolongedrelease tablets without lead-in period.
Slovenian: Bolniki, ki se že zdravijo s tabletami s takojšnjim sproščanjem ali peroralno suspenzijo, lahko zdravilo zamenjajo s tabletami s podaljšanim sproščanjem brez uvajalnega obdobja.
English: The difference in nevirapine pharmacokinetics observed when Viramune prolonged-release tablets are dosed under fasted or fed conditions is not considered clinically relevant.
Slovenian: Razlika v nevirapinovi farmakokinetiki, ki je posledica jemanja zdravila Viramune tablete s podaljšanim sproščanjem na tešče ali na poln želodec, ne velja za klinično pomembno.
English: Twenty per cent of patients assigned to nevirapine twice daily and 18% of patients assigned to efavirenz had at least one grade 3 or 4 clinical adverse event.
Slovenian: 20 % bolnikov, razvrščenih v zdravljenje z dvema odmerkoma nevirapina na dan in 18 % bolnikov, razvrščenih v zdravljenje z efavirenzem, je imelo najmanj en klinični neželeni učinek stopnje 3 ali 4.
English: Monitoring of hepatic tests should be done every two weeks during the first 2 months of treatment, at the 3
Slovenian: Preiskave jetrne funkcije je treba narediti vsaka dva tedna prva dva meseca zdravljenja, po tretjem mesecu in nato redno.
English: If you have a renal or hepatic dysfunction of any degree please use only Viramune 200 mg tablets or Viramune 50 mg/5 ml oral suspension.
Slovenian: Če imate ledvično ali jetrno okvaro katerekoli stopnje, uporabljajte samo zdravilo Viramune 200 mg tablete in zdravilo Viramune 50 mg/5 ml peroralna suspenzija.
English: The limited data available from a phase IIa study in HIV-infected patients have shown a clinically non significant 20% decrease of TPV Cmin.
Slovenian: Omejeni podatki iz raziskave faze IIa pri bolnikih okuženih s HIV kažejo na klinično nepomembno 20-odstotno zmanjšanje Cmin TPV.
English: Viramune is also available as 400 mg prolonged-release tablets for a once daily usage after the lead-in phase for children depending on their age and body weight (body surface area).
Slovenian: Zdravilo Viramune je za otroke na voljo tudi v obliki 400 mg tablet s podaljšanim sproščanjem, namenjenih jemanju enkrat na dan po končanem uvajalnem obdobju zdravljenja, v odmerku, ki je odvisen od starosti in telesne mase (telesne površine) otroka.
English: Rifabutin 150 or 300 mg QD
Slovenian: Rifabutin 150 ali 300 mg na dan
English: Table 2 describes week 48 outcomes in the VERxVE study (1100.1486).
Slovenian: Preglednica 2 vsebuje podatke o izidih zdravljenja po 48 tednih v študiji VERxVE (1100.1486).
English: * Includes patients who received at least one dose of blinded medicinal product after randomisation.
Slovenian: * Zajema bolnike, ki so prejeli vsaj en odmerek prikritega zdravila po naključni razvrstitvi.
English: If you ever have only mild rash symptoms without any other reaction please inform your doctor immediately, who will advise you whether you should stop taking Viramune.
Slovenian: Če opazite le blag izpuščaj, ki ga ne spremljajo druge reakcije, nemudoma obvestite svojega zdravnika, ki vam bo svetoval, ali morate zdravilo Viramune prenehati jemati.
English: Viramune belongs to a group of medicines called antiretrovirals, used in the treatment of Human Immunodeficiency Virus (HIV-1) infection.
Slovenian: Zdravilo Viramune sodi v skupino protiretrovirusnih zdravil, ki jih uporabljamo za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV-1).
English: Coadministration of telaprevir and medicinal products that induce CYP3A and/or P-gp may decrease telaprevir plasma concentrations.
Slovenian: Pri hkratnem dajanju telaprevirja in zdravil, ki inducirajo CYP3A in/ali P-gp , se lahko zmanjša koncentracija telaprevirja v plazmi.
English: They should be informed that occurrence of symptoms suggestive of hepatitis should lead them to discontinue nevirapine and immediately seek medical evaluation, which should include liver function tests.
Slovenian: Poučiti jih je treba, da morajo ob pojavu simptomov, ki kažejo na hepatitis, prenehati jemati nevirapin in da je potrebna takojšnja zdravniška ocena njihovega zdravstvenega stanja, ki mora vključevati tudi preiskave jetrnega delovanja.
English: You must take Viramune together with other antiretroviral medicines.
Slovenian: Zdravilo Viramune morate jemati hkrati z drugimi protiretrovirusnimi zdravili.
English: The first 18 weeks of treatment is a critical period which requires close monitoring (see section 4.4).
Slovenian: Prvih 18 tednov zdravljenja je kritično obdobje, v katerem moramo bolnika skrbno opazovati (glejte poglavje 4.4).
English: Viramune 400 mg prolonged-release tablets can be taken by children if they: - are  8 years of age and weigh 43.8 kg or more - are older than 3 years of age and below 8 years of age and weigh 25 kg or more - have a body surface area of 1.17 square metres or above.
Slovenian: Zdravilo Viramune 400 mg tablete s podaljšanim sproščanjem lahko jemljejo otroci, če: - so stari  8 let in imajo telesno maso 43,8 kg ali več - so starejši od 3 let in mlajši od 8 let in imajo telesno maso 25 kg ali več - je njihova telesna površina 1,17 m2 ali več.
English: When rash occurs it is normally mild to moderate.
Slovenian: Če se izpuščaj pojavi, je večinoma blag do zmerno hud.
English: Genotypic analysis of isolates from antiretroviral naïve patients experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine for 48 weeks showed that isolates from 8/25 and 23/46 patients, respectively, contained one or more of the following NNRTI resistance-associated substitutions:
Slovenian: Genotipske analize izolatov, odvzetih bolnikom, ki prej še niso prejemali protiretrovirusnih zdravil, pri katerih je prišlo do virološkega neuspeha (n = 71), prejemali pa so nevirapin enkrat na dan (n = 25) ali dvakrat na dan (n = 46) v kombinaciji z lamivudinom in stavudinom 48 tednov, so pokazale, da so izolati 8/25 oziroma 23/46 bolnikov vsebovali eno ali več naslednjih substitucij, povezanih z odpornostjo proti nenukleozidnim zaviralcem reverzne transkriptaze:
English: Significantly fewer patients in the abacavir group (9 patients, or 6 %) than in the nevirapine group (26 patients, or 17 %) or the efavirenz group (27 patients, or 17 %) discontinued the medicinal product because of adverse events.
Slovenian: V skupini z abakavirjem jih je značilno manj bolnikov (9 bolnikov ali 6 %) prenehalo jemati zdravilo zaradi neželenih učinkov kot v skupini z nevirapinom (26 bolnikov ali 17 %) ali efavirenzem (27 bolnikov ali 17 %).
English: They should be advised to promptly notify their physician of any rash and avoid delay between the initial symptoms and medical consultation.
Slovenian: Svetovati jim je treba, naj zdravnika obvestijo o vsakem izpuščaju in ob pojavu začetnih simptomov ne odlagajo obiska pri zdravniku.
English: Depending on the outcome your doctor may decide to interrupt or stop Viramune treatment.
Slovenian: Glede na izvide se lahko odloči za prekinitev ali ukinitev zdravljenja z zdravilom Viramune.
English: The pharmacokinetics of Viramune prolonged-release was assessed in study 1100.1518.
Slovenian: Farmakokinetiko zdravila Viramune s podaljšanim sproščanjem so ocenjevali v študiji 1100.1518.
English: The interaction data is presented as geometric mean value with 90% confidence interval (90% CI) whenever these data were available.
Slovenian: Podatki o interakcijah so povsod, kjer so bili dosegljivi, navedeni kot geometrične srednje vrednosti z 90-odstotnim intervalom zaupanja (90-odstotni IZ).
English: Methyl and propyl parahydroxybenzoates: Viramune oral suspension contains methyl parahydroxybenzoate and propyl parahydroxybenzoate, which may cause allergic reaction (possibly delayed).
Slovenian: Metil- in propilparahidroksibenzoat: Zdravilo Viramune peroralna suspenzija vsebuje metilparahidroksibenzoat in propilparahidroksibenzoat, ki lahko povzročita alergijsko reakcijo (ki je lahko zapoznela).
English: After 14 days, the usual dose is one 200 mg tablet twice a day.
Slovenian: Po 14 dneh je običajni odmerek ena tableta po 200 mg 2-krat na dan.
English: If patients experience fatigue they should avoid potentially hazardous tasks such as driving or operating machinery.
Slovenian: Če bodo bolniki utrujeni, se morajo izogibati dejavnostim, ki so lahko nevarne, na primer vožnji ali upravljanju strojev.
English: Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs).
Slovenian: Večina izkušenj z zdravilom Viramune izvira iz kombiniranega dajanja z nukleozidnimi zaviralci reverzne transkriptaze (NRTI).
English: The recommended oral doses for paediatric patients based upon their weight are described in the table below.
Slovenian: Priporočeno peroralno odmerjanje za otroke na podlagi telesne površine je opisano v spodnji tabeli.
English: One side is marked with the code “54 193”, with a single bisect separating the “54” and “193”.
Slovenian: Na eni strani je oznaka »54 193«, pri kateri sta številki »54« in »193« ločeni z enojno zarezo.
English: Therefore, patients who receive nevirapine and zidovudine concomitantly and especially paediatric patients and patients who receive higher zidovudine doses or patients with poor bone marrow reserve, in particular those with advanced HIV disease, have an increased risk of granulocytopenia.
Slovenian: Če bolniki sočasno prejemajo nevirapin in zidovudin, predvsem pediatrični bolniki in bolniki, ki se zdravijo z večjimi odmerki zidovudina ali imajo zmanjšano rezervo kostnega mozga, obstaja pri njih povečano tveganje pojava granulocitopenije, zlasti če imajo napredovalo bolezen zaradi okužbe s HIV.
English: system.
Slovenian: Stopnje.
English: If ASAT or ALAT increase to > 5 ULN during treatment, nevirapine should be immediately stopped.
Slovenian: Če se raven ASAT ali ALAT med zdravljenjem poveča na > 5-kratno zgornjo mejo normalne vrednosti, moramo zdravljenje z nevirapinom nemudoma ukiniti.
English: Data reported in the literature from 20 HIV-infected patients suggest a steady state Cmax of 5.74 µg/ml (5.00-7.44) and Cmin of 3.73 µg/ml (3.20-5.08) with an AUC of 109.0 h*µg/ml (96.0-143.5) in patients taking 200 mg of nevirapine bid.
Slovenian: Podatki iz literature za 20 s HIV okuženih bolnikov kažejo, da je Cmax v ravnovesnem stanju 5,74 µg/ml (5,00 do 7,44), Cmin 3,73 µg/ml (3,20 do 5,08) in AUC 109,0 h*µg/ml (96,0 do 143,5) pri bolnikih, ki jemljejo po 200 mg nevirapina 2-krat na dan.
English: Each bottle contains 2.4 g of nevirapine (as hemihydrate) in 240 ml of Viramune oral suspension.
Slovenian: Ena plastenka vsebuje 2,4 g nevirapina (v obliki hemihidrata) v 240 ml zdravila Viramune peroralna suspenzija.
English: What Viramune looks like and contents of the pack
Slovenian: Izgled zdravila Viramune in vsebina pakiranja
English: Viramune should not be used as the sole active antiretroviral, as monotherapy with any antiretroviral has shown to result in viral resistance.
Slovenian: Zdravila Viramune ne smemo uporabljati kot edino aktivno protiretrovirusno zdravilo, ker se je pokazalo, da se pri monoterapiji s katerimkoli protiretrovirusnim zdravilom razvije virusna odpornost.
English: Inform your doctor about all other medicines you are taking before you start taking Viramune.
Slovenian: Zdravnika obvestite o vseh zdravilih, ki jih jemljete, preden boste začeli jemati zdravilo Viramune.
English: HIV-1 isolates with reduced susceptibility (100-250-fold) to nevirapine emerge in cell culture.
Slovenian: V celični kulturi se pojavljajo izolati HIV-1 z zmanjšano občutljivostjo (100- do 250-krat) za nevirapin.
English: Use caution when engaging in activities such as driving, using any tools or machines.
Slovenian: Bodite previdni pri dejavnostih, kot so vožnja ter uporaba kakršnihkoli orodij ali strojev.
English: Asymptomatic GGT elevations are not a contraindication to continue therapy.
Slovenian: Nesimptomatično povečanje gama-glutamiltransferaze (GGT) ni kontraindikacija za nadaljevanje zdravljenja.
English: Viramune should be combined with at least two additional antiretroviral agents.
Slovenian: Zdravilo Viramune je treba kombinirati vsaj z dvema dodatnima protiretrovirusnima zdraviloma.
English: Table 1: Demographic and Baseline Disease Characteristics in study 1100.1486 Viramune immediate-release
Slovenian: Demografski podatki in izhodiščne značilnosti bolezni v raziskavi 1100.1486 Zdravilo Viramune s takojšnjim sproščanjem
English: In vitro studies with human liver microsomes suggest that oxidative metabolism of nevirapine is mediated primarily by cytochrome P450 isozymes from the CYP3A family, although other isozymes may have a secondary role.
Slovenian: Raziskave in vitro s človeškimi jetrnimi mikrosomi kažejo, da poteka oksidacijska presnova nevirapina pretežno prek izoencimov citokroma P450 iz skupine CYP3A, čeprav imajo lahko sekundarni pomen pri presnovi tudi drugi encimi.
English: Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Slovenian: Pri nekaterih bolnikih, ki jemljejo kombinirano protiretrovirusno zdravljenje, se lahko razvije kostna bolezen, ki jo imenujemo osteonekroza (odmiranje kostnega tkiva, ki je posledica neprekrvljeenosti kosti).
English: Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities.
Slovenian: Izpuščaj je običajno blag do zmerno hud, v obliki makulopapularnih eritemskih kožnih erupcij, s srbežem ali brez njega, ki se pojavi na trupu, obrazu in okončinah.
English: The 14-day”lead-in” period has been shown to lower the risk of skin rash.
Slovenian: Pokazalo se je, da 14-dnevno ”uvajalno” obdobje zmanjša tveganje kožnega izpuščaja.
English: Overall, the exposure in children was similar to that observed in adults receiving Viramune prolonged-release in study 1100.1486.
Slovenian: Izpostavljenost je bila pri otrocih podobna kot pri odraslih, ki so prejemali zdravilo Viramune s podaljšanim sproščanjem v študiji 1100.1486.